[Drug safety. Notes about surveillance].
Moreno Alvarez
P J
PJ
Centro de Documentación, Sociedad Española de Farmacia Hospitalaria, Madrid, 28020, Spain. pmorenoal@sefh.es
Madurga Sanz
M
M
D000707:Anaphylaxis / Q000139:chemically induced; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects; D000998:Antiviral Agents / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology; D064420:Drug-Related Side Effects and Adverse Reactions; D006629:Hirudins / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D000069455:Palivizumab; D010879:Piperazines; D011358:Product Surveillance, Postmarketing; D011994:Recombinant Proteins / Q000009:adverse effects; D014230:Triazoles / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018687:Antidepressive Agents, Second-Generation; D000998:Antiviral Agents; D006629:Hirudins; D010879:Piperazines; D011994:Recombinant Proteins; D014230:Triazoles; C051752:nefazodone; D000069455:Palivizumab; C083544:lepirudin